14 results about "Ginkgolide-B" patented technology

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The invention provides a pharmaceutical composition, a preparation as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises bilobalide B and dextroborneol, the weight ratio of the bilobalide B to the dextroborneol is (0.02 to 50): 1. In the pharmaceutical composition disclosed by the invention, bilobalide B and dextroborneol can play a synergistic effect, and the pharmaceutical composition has an excellent effect, small side effects and an excellent clinical application prospect when being used for treating cerebral arterial thrombosis; the traditional Chinese medicine composition is novel in formula, simple in component, clear in action mechanism, remarkable in curative effect, not prone to tolerance generation and capable of achieving large-scale industrial production.

The invention relates to the technical field of biology, and particularly discloses application of bilobalide B in plateau environment cognitive dysfunction protection. The application comprises the steps that a pharmaceutical composition containing bilobalide B is mixed with a low-concentration oxygen adaptation regulating agent to be used for regulating the pharmaceutical composition, and an intermediate product with the nerve protection enhancing effect is obtained; carrying out nano-carrier packaging and functionalization treatment on the intermediate product with the effect of enhancing neuroprotection, so as to realize brain-targeted controlled release of the drug to obtain a composite controlled release drug; the compound controlled-release medicine is administrated by adopting an administration dosage optimization method based on reinforcement learning, so that long-term prevention and improvement of cognitive impairment in a plateau environment are realized, and a final cognitive function protection effect is obtained; the whole formula is regulated and controlled by a nano controlled release technology, and all the components can be continuously released and uniformly distributed, so that the optimal balance between the drug effect and the safety is realized, and the problem of cognitive impairment caused by high altitude hypoxia is comprehensively improved.

The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and / or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w / w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w / w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w / w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w / w of the composition. Such compositions are useful for improving memory and / or focus.

The invention provides application of bilobalide B in inhibiting cerebral ischemia reperfusion injury caused by ferroptosis, and relates to the field of cerebral ischemia reperfusion injury. According to the application, ginkgolide B inhibits ferroptosis by regulating an Nrf2 / H0-1 pathway so as to improve cerebral ischemia reperfusion injury, regulation of Nrf2 / H0-1 promotes nuclear translocation of Nrf2 and up-regulates expression of a downstream antioxidant gene HO-1 so as to relieve spinal cord injury by inhibiting ferroptosis, and up-regulation of the expression of the downstream antioxidant gene HO-1 is that when cells are stimulated by hypoxia, the expression of the downstream antioxidant gene HO-1 is inhibited so as to inhibit the ischemia reperfusion injury. And the Nrf2 is dissociated from the Keap1 and is translocated to a cell nucleus. The action mechanism of the ginkgolide B for inhibiting the ferroptosis process and improving the CIRI by regulating and controlling an Nrf2 / HO-1 signal channel is explored, and a research strategy of combining bioinformatics prediction and experimental verification is adopted, so that a foundation is laid for deeply analyzing the neuroprotective action mechanism of the ginkgolide B; and a new research thought and a potential target spot are provided for developing a novel ginkgo leaf-related active ingredient medicine.

The present invention relates to the technical field of medicine, and to derivatives represented by formula 1 and formula 2 in which a carboxylic acid group is introduced into the structure of Ginkgolide B by means of a hydroxyl group at the 10-position and ester derivatives of carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts. Ginkgolide B is used as a parent body and is prepared by means of chemical structure modification so as to achieve the goals of improving solubility, increasing bioavailability and enhancing healing efficacy. The prepared compound and carboxylate salts thereof have significant platelet activating factor antagonism, an anticoagulant effect and an anti-acute cerebral ischemia effect, and can be used for preparing a drug for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, as well as inflammation, asthma and other diseases related to a platelet activating factor.

The present application provides a kind of pharmaceutical composition for vulvar sclerosing lichen and its preparation method, the pharmaceutical composition includes active ingredient and pharmaceutically acceptable vulva local administration adjuvant, active ingredient is made of 0.005-0.02 parts of mometasone furoate, 0.05-0.3 parts of calcineurin inhibitor, 0.5-2 parts of paeoniflorin, 0.8-3 parts of asiaticoside, 0.3-1.5 parts of recombinant collagen, 0.2-1 part of ginkgolide B.The present application is aimed at the core pathogenesis of disease, constructs multi-target whole course of disease synergistic therapy system, can realize anti-inflammatory regulation, anti-fibrosis, basement membrane repair, microcirculation improvement simultaneously, low-dose strong effect, greatly reduce side effect and recurrence rate;Liposome targeted delivery technology is used, the stability of active ingredient is guaranteed, process controllable adaptation industrialization production, and clinical application prospect is wide.

The present invention relates to a synergistic composition for controlling headache disorders. The composition comprises Palmitoylethanolamide, Magnesium, and Ginkgolide B, along with pharmaceutically acceptable excipients. The invention addresses primary headache disorders, including migraine and tension-type headaches, which represent the majority of headache disorders. Palmitoylethanolamide exhibits analgesic and anti-inflammatory properties, down¬ regulating pro-inflammatory and nociceptive pathways. Magnesium contributes to the reduction of headache symptoms, while Ginkgolide B, derived from Ginkgo biloba, enhances the therapeutic effect. Animal studies have demonstrated the synergistic efficacy of this combination in reducing the frequency, duration, and severity of headache symptoms, both independently and when used with standard treatments.

The present invention relates to a method for extracting and purifying ginkgolide B. The method comprises: (1) crushing ginkgo leaves, adding a mixed acid solution for soaking and extraction; (2) concentrating ginkgo leaf extract 1, boiling, adding talcum powder, filtering, refrigerating, and filtering; (3) adding ethyl acetate to extract 2, separating the layers, adding water, separating the layers, filtering, and spin-drying; (4) dissolving the crude extract in ethanol, eluting through a superacidic alumina chromatography column; (5) concentrating the eluate, refrigerating, filtering, and drying; (6) adding the crude ginkgolide B to a mixed solution of n-heptane and ethanol for crystallization. This method not only solves the problems of low extraction rate in steam distillation and large amount of solvent loss in organic solvent extraction, but also improves the yield of ginkgolide B while ensuring the purity of ginkgolide B. It has the advantages of simple preparation process, easy operation, low organic solvent consumption, low cost, high yield and purity, and is suitable for industrial production.

The invention discloses a biological nano-drug with blood platelets carrying bilobalide and butylphthalide as well as a preparation method and application of the biological nano-drug, and relates to the technical field of pharmaceutical preparations. The biological nano-drug comprises an active component, a core drug carrier, a biological shell and targeting polypeptide, the active component at least comprises bilobalide B and butylphthalide, the core drug carrier comprises a lipid carrier, the targeting polypeptide is CITP peptide, the mass ratio of the active component to the core drug carrier is 1: 5-1: 10, the amino acid sequence of the CITP peptide is PHSSHIGTTEIGKL, and the amino acid sequence of the CITP peptide is HSSHIGTTEIGKL. The biological shell comprises at least one of a platelet membrane and an exosome membrane. The biological nano-drug disclosed by the invention is good in targeting property and good in treatment effect, and a new thought is provided for treating thrombotic diseases.

The present invention relates to the technical field of natural product purification, and more specifically, to a method for preparing ginkgolide B and a purified product. The method comprises: mixing a ginkgolide extract with water, boiling the mixture, cooling and filtering the mixture to form a precipitate, then mixing and dissolving the precipitate with a hot alcohol solvent, and then cooling and filtering the mixture. The ginkgolide B prepared by this method has higher purity and yield, is simpler, pollution-free, and more suitable for large-scale production.

The application discloses a kind of functionalization exosome-traditional Chinese medicine small molecule composite preparation T-pEXOs@GB and its preparation method and application.The composite preparation encapsulates ginkgolide B (GB) in the exosome of healthy plasma, and is functionally modified neuron target peptide RVG (DSPE-PEG-RVG) on its surface, so that it has brain targeting and oxygen supply functions.The preparation method provided by the application can efficiently and controllably prepare the composite preparation with uniform particle size and good stability.The T-pEXOs@GB composite preparation of the application can be targeted to deliver to brain ischemia and hypoxia injury area, significantly reduce oxidative stress and inflammatory response, reduce cerebral infarction volume, improve neurological deficit score, and improve the survival rate of animal model, and can be used to prepare drugs for preventing and treating acute high altitude cerebral hypoxia, ischemic stroke, neonatal hypoxic-ischemic encephalopathy and other cerebral ischemia and hypoxia injury, and has good market prospect.

This invention discloses a platelet-loaded bio-nanomedicine containing ginkgolide and butylphthalide, its preparation method, and its application, relating to the field of pharmaceutical formulation technology. The bio-nanomedicine comprises an active ingredient, a core drug carrier, a biological shell, and a target-seeking peptide. The active ingredient includes at least ginkgolide B and butylphthalide. The core drug carrier includes a lipid carrier, and the target-seeking peptide is a CITP peptide. The mass ratio of the active ingredient to the core drug carrier is 1:5 to 1:10. The amino acid sequence of the CITP peptide is PHSSHIGTTEIGKL. The biological shell includes at least one of platelet membrane and exosome membrane. The bio-nanomedicine of this invention exhibits good targeting and therapeutic efficacy, providing a new approach for the treatment of thrombotic diseases.

The invention discloses graphene oxide loaded bilobalide B and a preparation method thereof. The graphene oxide loaded bilobalide B comprises graphene oxide, a polymer, bilobalide B and ferritin, the graphene oxide, the polymer and the ferritin are subjected to covalent bond grafting to complete functional modification, so that the stability and the biocompatibility are improved; the graphene oxide is modified by the polymer NPs to obtain the flaky graphene oxide / polymer NPs, so that the dispersity and biocompatibility of the graphene oxide are greatly improved; modifying the graphene oxide through protein to obtain a dual-modified targeted graphene oxide drug delivery system; the bilobalide B is loaded on the dual-modified targeted graphene oxide, so that the problem of poor solubility of the bilobalide B is greatly improved, and meanwhile, the drug loading capacity of the bilobalide B is also improved; the preparation method and the production process are relatively simple, the yield is high, and a final product solvent is water and is non-toxic.